Replies to post #74 on $Fire$ Eaters

[subslover]

Geron Is Ripe For A Short Squeeze
Jun. 29, 2015 10:02 AM ET | 2 comments | About: Geron Corporation (GERN), Includes: JNJ
Disclosure: I am/we are long GERN. (More...)
Summary

Short interest in Geron has risen in the last two months.
At the same time, short ratio is also very high, making Geron ripe for a short squeeze.
A short squeeze could be triggered by an update on Geron’s plans to acquire oncology products.
Short interest in Geron Corporation (NASDAQ:GERN) has risen sharply since the company reported its Q1 results and provided an update on April 30th. Short interest has risen almost 8% between April 30th and June 15th. But so has the days to cover or short ratio. With two upcoming catalysts, this makes Geron ripe for a short squeeze.

According to data from NASDAQ, a total of 25,479,050 shares of Geron were shorted on April 30th, 2015, with short ratio at 8.72. Average daily share volume at the time was 2,919,707. On April 30th, Geron reported its Q1 results and provided an update on its collaboration with Janssen (NYSE:JNJ). The company also announced that it will reduce its workforce in the wake of the Janssen agreement. On May 15th, the number of shorted shares rose to Average daily volume has also come down sharply from almost 3 million at the end of April to 2.14 million. The decline in volume is a bit surprising as the company has held a conference call in this period and also imetelstat has been granted an Orphan Drug Designation by the FDA in MF. The conference call with shareholders was held in May, which I discussed here. Although Geron did address some of the questions that I had raised in a previous article, some questions remain unanswered. I also tried to interview Dr Ayalew Tefferi, who is very relevant to Imet's MF program - but no response from the doctor yet. Geron also did not shed any light on plans to acquire new oncology products. Also, not much was discussed on the '615 patent.

Having said that, the second half could become livelier for Geron and its shareholders. Indeed, there are at least two upcoming catalysts that would be of concern to short sellers. Janssen is on track to start the Phase 2 200-patient MF study. By the end of this year, Janssen is expected to commence the MDF Phase 2 study. But what will possibly trigger a short squeeze in my opinion is an update on Geron's plans to acquire oncology products. I believe that it would make sense for long-term investors to add to their position in Geron and take some quick profit from a short squeeze.

E*TRADE: Become A Smarter Investor.

[subslover]

Imageware Systems Announces License Agreement With Lockheed Martin [Market News Publishing (US)]

LOCKHEED MARTIN CORP

IMAGEWARE SYSTEMS INC ("IWSY-0") LOCKHEED MARTIN ("LMT-N") - Imageware Systems Announces License Agreement With Lockheed - Martin

Imageware Systems, Inc. (ImageWare), a leader in mobile and cloud-based, multi-modal biometric identity management solutions, has executed a three year licensing agreement with Lockheed Martin under which ImageWare will integrate its patented Biometric Engine(r) into the Lockheed Martin cloud-based multimodal biometric, IDHaystack(SM) Identity as a Service (IDaaS) Platform. Lockheed Martin will offer the identity service to the federal government and other customers through its FedRAMP approved government community cloud -- SolaS(r).

"Lockheed Martin is a well-recognized, world class company and we both pride ourselves on delivering superior world class biometric products and technology to our markets and partners," said Jim Miller, Imageware's chairman and CEO. "We believe that the IWS Biometric Engine will provide our partners at Lockheed Martin with a distinct advantage as they pursue opportunities in the Identity Management market."

"The IDHaystack(SM) service is an innovative new way to offer open backend storage and matching capabilities to support virtually any biometric-enabled operation using one or more customer-selected algorithms for common as well as advanced biometrics," said John Mears, senior fellow, IT and security solutions at Lockheed Martin. "Partnering with ImageWare Systems allows us to more quickly offer advanced, secure, cloud-based capability to our customers and to their missions."

About ImageWare Systems, Inc.

Headquartered in San Diego, California, ImageWare is a leading provider of identity management solutions driven by multi-modal biometrics. We deliver multi-modal biometric identity management solutions for user authentication on premises and in the cloud. Our patented, agnostic, plug-n-play technology promotes interactive communication and Out-Of-Band authentication on mobile platforms and brings security to an all new level. Our innovative products, such as GoCloudID(r) and GoMobile Interactive(r), enable modular, flexible, and scalable identity solutions across a variety of markets, including mobile, wireless, financial services, and healthcare. ImageWare's identity management system allows customers to easily add a secure layer of biometric authentication to a variety of platforms and services. For more information about ImageWare Systems, Inc., please visit www.iwsinc.com.

NYSE closing price for LMT-N Date: 2015/07/13 Closing Price: 197.88

____________________________________________________________
(c)2015 Market News Publishing Inc. All rights reserved.
Toronto:[phone] Vancouver:[phone] Fax:[phone]
© (c) 2015 Market News Publishing Inc.
< Back


Our Marketplaces



Market Info
Contact Us
Advertising
Market Hours/Holidays
Corporate Info
About Us
Investor Relations
Press Center
Careers
Sign up for the Newsletter

View Previous Newsletters

Follow Us:
© 2015 OTC Markets Group Inc.Terms of ServiceLinking TermsTrademarksPrivacy StatementRisk WarningSite MapGive FeedbackSupported Browsers? Jump to Top

OTC Link® ATS provided by OTC Link LLC, member FINRA / SIPC, a wholly owned subsidiary of OTC Markets Group Inc.
OTCQX, OTCQB and OTC Pink marketplaces designated by OTC Markets Group.

AdTech Ad